New study tests clinic strategies to curb HIV and infections in drug users
NCT ID NCT07073924
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to help outpatient clinics provide HIV prevention medication (PrEP) and sterile injection equipment to people who inject drugs. Researchers will work with clinics to develop and test a bundle of strategies, including patient education, provider training, and system changes. The goal is to reduce HIV and serious injection-related infections. The trial will involve 536 participants across multiple clinic sites.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- behavioral intervention (education, peer support, provider training, policy changes)
- What this could lead to
- If successful, this could provide a practical model for clinics to reduce HIV and serious infections among people who inject drugs.
- What could go wrong
- This is an early pilot study focused on implementation, not direct health outcomes. The strategies may not be adopted widely or may not reduce infections as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 536 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Patients: Pre-implementation interviews (N=12), pre-implementation focus groups (N=8), and post-implementation interviews (N=10) Inclusion Criteria: -Adult patients with history of active injection drug use in the past 1 year from the 4 COEs Exclusion Criteria: * Ages \<18 * If history of injection drug use \>1 year * Non-English speaking * Pending or legal action that could prohibit or interfere with participation (Ie. incarceration) * Residence or discharge to a treatment facility that bans the possession of drug checking supplies * Acute, severe psychiatric condition in need of immediate treatment. Clinical Partners: Pre-implementation interviews (N=12), pre-implementation focus groups (N = 24), post-implementation surveys (N = 80), and post-implementation interviews (N=10) Inclusion Criteria: -Prescribing clinicians (e.g., physicians, advanced practice providers such as nurse practitioners and physician assistants), administrators, medical assistants, and nurses from the 4 COEs Exclusion Criteria: * Individuals not affiliated with the 4 COEs. * Staff outside the specified roles (i.e., not prescribing clinicians, administrators, medical assistants, or nurses). * Students, trainees, or individuals not credentialed in the eligible roles. * Those on extended leave or not actively working during the study period.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for People who use opioids/people with opioid use disorder (OUD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Center for Psychiatric And Chemical Dependency Services
Pittsburgh, Pennsylvania, 15213, United States
-
Internal Medicine Recovery Engagement Program
Pittsburgh, Pennsylvania, 15213, United States
-
Latterman Family Health Center
Pittsburgh, Pennsylvania, 15132, United States
-
UPMC Magee-Womens Hospital
Pittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.